Patent Attorney's Docket No. <u>030708-035</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RE	C	<b>E1</b>	V	E	D

In re Patent Application of	)	OCT 3 0 2001
Peter SONDEREGGER	) Group Art Unit: 1646	TECH CENTER 1600/2900
Application No.: 09/403,724	) Examiner: O. Chernyshev	.1
Filed: October 26, 1999	)	12/0
For: NEUROTRYPSIN	)	J.9J

## **REPLY AND AMENDMENT**

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In complete response to the Official Action issued July 26, 2001, please amend the above-identified application as follows:

## **IN THE ABSTRACT:**

Please insert the Abstract of the Disclosure attached to the end of the Reply and Amendment at the end of the application papers.

## **IN THE SPECIFICATION:**

Page 1, amend the fifth full paragraph (beginning at line 17, shown as line 26 on the page) as follows:

The newly found neurotrypsins

- neurotrypsin of the human (compound of the formula I, SEQ ID NO: 1),
- neurotrypsin of the mouse (compound of the formula II, SEQ ID NO: 3) differ structurally very much from the so far known serine proteases.